MA41090A - Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson - Google Patents

Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson

Info

Publication number
MA41090A
MA41090A MA041090A MA41090A MA41090A MA 41090 A MA41090 A MA 41090A MA 041090 A MA041090 A MA 041090A MA 41090 A MA41090 A MA 41090A MA 41090 A MA41090 A MA 41090A
Authority
MA
Morocco
Prior art keywords
adhd
parkinson
antagonist
dose
disease
Prior art date
Application number
MA041090A
Other languages
English (en)
Inventor
Johan Areberg
Nathalie Breysse
Gamini Chandrasena
Lone Frydelund Larsen
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA41090A publication Critical patent/MA41090A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
MA041090A 2014-12-03 2015-11-30 Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson MA41090A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201400704 2014-12-03

Publications (1)

Publication Number Publication Date
MA41090A true MA41090A (fr) 2017-10-10

Family

ID=58731664

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041090A MA41090A (fr) 2014-12-03 2015-11-30 Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson

Country Status (25)

Country Link
US (2) US20160158211A1 (fr)
EP (1) EP3226863A1 (fr)
JP (1) JP2017536400A (fr)
KR (1) KR20170090430A (fr)
CN (1) CN106999480A (fr)
AU (1) AU2015357197A1 (fr)
BR (1) BR112017011777A2 (fr)
CA (1) CA2966582A1 (fr)
CL (1) CL2017001407A1 (fr)
CO (1) CO2017004785A2 (fr)
CR (1) CR20170221A (fr)
DO (1) DOP2017000121A (fr)
EA (1) EA201790973A1 (fr)
EC (1) ECSP17030050A (fr)
IL (1) IL252355A0 (fr)
MA (1) MA41090A (fr)
MX (1) MX2017007027A (fr)
NI (1) NI201700066A (fr)
PE (1) PE20170926A1 (fr)
PH (1) PH12017500923A1 (fr)
SG (1) SG11201704370XA (fr)
SV (1) SV2017005441A (fr)
TN (1) TN2017000174A1 (fr)
TW (1) TW201632186A (fr)
WO (1) WO2016087429A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020010197A1 (fr) 2018-07-05 2020-01-09 Incyte Corporation Dérivés de pyrazine fusionnés en tant qu'inhibiteurs d'a2a/a2b
MX2021008094A (es) 2019-01-11 2021-09-21 Omeros Corp Metodos y composiciones para el tratamiento del cancer.
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CN114917350B (zh) * 2022-06-21 2023-06-13 重庆医科大学附属第二医院 Cftr增强剂在注意缺陷与多动障碍中的应用及产品

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4638355B2 (ja) * 2003-12-26 2011-02-23 協和発酵キリン株式会社 チアゾール誘導体
KR20110040856A (ko) * 2008-07-23 2011-04-20 교와 핫꼬 기린 가부시키가이샤 편두통 치료제
TWI548411B (zh) * 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
UA110097C2 (uk) * 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
UA113383C2 (xx) * 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів

Also Published As

Publication number Publication date
JP2017536400A (ja) 2017-12-07
TN2017000174A1 (en) 2018-10-19
DOP2017000121A (es) 2017-07-15
US20180125835A1 (en) 2018-05-10
EA201790973A1 (ru) 2017-10-31
PH12017500923A1 (en) 2017-11-20
ECSP17030050A (es) 2017-08-31
AU2015357197A1 (en) 2017-05-25
IL252355A0 (en) 2017-07-31
PE20170926A1 (es) 2017-07-13
EP3226863A1 (fr) 2017-10-11
CA2966582A1 (fr) 2016-06-09
US20160158211A1 (en) 2016-06-09
NI201700066A (es) 2018-01-04
BR112017011777A2 (pt) 2018-02-20
SG11201704370XA (en) 2017-06-29
TW201632186A (zh) 2016-09-16
KR20170090430A (ko) 2017-08-07
WO2016087429A1 (fr) 2016-06-09
MX2017007027A (es) 2017-08-24
CO2017004785A2 (es) 2017-08-31
CL2017001407A1 (es) 2018-01-05
CR20170221A (es) 2017-10-05
SV2017005441A (es) 2017-08-25
CN106999480A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
EP3452166A4 (fr) Stimulation intranasale pour le traitement de la maladie de la glande de meibomius et de la blépharite
EP2978446A4 (fr) Procédés et agents pour le traitement de la maladie d'alzheimer
EP3644996A4 (fr) Procédés de traitement de la maladie de huntington
IL246917B (en) Biomarker and early diagnosis methods for Alzheimer's disease
EP3341391A4 (fr) Compositions et procédés pour le traitement de la douleur
MA41115A (fr) Procédé de traitement de la maladie d'alzheimer
GB201504432D0 (en) Materials and methods for diagnosis and treatment of alzheimers disease
HUE063369T2 (hu) Vegyületek Alzheimer-kór kezelésében történõ alkalmazásra APOE4+/+ betegekben
EP3347486A4 (fr) Réduction du fragment c99 de l'app localisé sur la membrane er-mam et procédés de traitement de la maladie d'alzheimer
EP3347492A4 (fr) Procédés pour le diagnostic histologique et le traitement de maladies
PL3277280T3 (pl) Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
EP3546449A4 (fr) Dérivé de pipéridine -2,6-dicétone et traitement de la maladie de crohn
EP3395341A4 (fr) Composition pour le traitement de maladies neuromotrices et son utilisation
EP3341079A4 (fr) Procédés et compositions pour le diagnostic et le traitement du cancer
GB201504387D0 (en) Materials and methods for the treatment of vascular disease
EP3398614A4 (fr) Agent pour la prévention et/ou le traitement de la maladie d'alzheimer
MA41090A (fr) Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson
FR3022139B1 (fr) Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee
PL3449009T3 (pl) Biomarkery mikroRNA we krwi do diagnozowania choroby Alzheimera
IL265911A (en) Epilimod preparations and methods of using them in the treatment of Alzheimer's disease
IL248935A0 (en) Diagnostic testing and treatment/prevention of Alzheimer's disease
FR3044227B1 (fr) Derives aminophosphiniques pour la prevention et le traitement des douleurs oculaires
IL254252A0 (en) History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease
EP3518914A4 (fr) Compositions et procédés pour traiter la maladie d'alzheimer et la maladie de parkinson
EP3334424A4 (fr) Compositions et procédés pour le traitement de l'alopécie